Abstract 712TiP
Background
CDK7, part of the CAK complex regulates cell cycle progression, making it a potential therapeutic target for malignancies with aberrant cell cycle regulation. Cell cycle arrest in cancer cells affects DNA damage repair and genomic instability, potentially triggering apoptosis and anti-tumor immune response. Q901, is a potent covalent CDK7 inhibitor, with demonstrated in vivo activity against resistant models, and has potential as a treatment for various cancers where standard care has failed.
Trial design
This phase 1/2 multicenter, open-label study (NCT05394103) evaluates the safety, pharmacodynamics, and pharmacokinetics of Q901 in adult patients with solid tumors in the USA and Korea. In phase 1 dose escalation, Q901 is administered intravenously once weekly for four weeks, then once every two weeks in patients with advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancers. The study will establish the MTD, DLT, and RP2D of Q901 monotherapy, using a modified Toxicity Probability Interval (mTPI) design targeting a DLT rate of ∼30%. Up to 6 dose levels/50 patients will be evaluated in phase 1. Upon determining the RP2D, the study advances to phase 2. Cohort 1 will recruit HR+ HER2- breast cancer patients receiving Q901 combined with fulvestrant, who have received at prior endocrine and CDK4/6 targeted treatment, along with up to two additional prior lines of systemic anticancer therapy. Cohort 2 consists of extensive-stage SCLC patients treated with Q901 monotherapy after failing first-line standard of care. Each cohort will enroll up to 20 patients to assess safety and activity in selected cancer types.
Clinical trial identification
NCT05394103.
Editorial acknowledgement
Legal entity responsible for the study
Qurient Co. Ltd.
Funding
Qurient Co. Ltd.
Disclosure
B. Choi, J. Ahn, J. Choi, K. Ahn, S. Ryu, J. Kim, D. Yu, S-J. Lee, B. Jeon, S. Proniuk, J. Kim, K. Nam: Financial Interests, Personal, Full or part-time Employment: Qurient Co. Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17
710P - A retrospective study on the safety and adequacy of fresh biopsies for next generation sequencing in early-phase clinical trials
Presenter: Edoardo Crimini
Session: Poster session 17
711TiP - A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Presenter: Andrew Weickhardt
Session: Poster session 17
713TiP - A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
Presenter: Ibiayi Dagogo-Jack
Session: Poster session 17
714TiP - A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
Presenter: Stephen Luen
Session: Poster session 17
715TiP - ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Presenter: Yan Wang
Session: Poster session 17
716TiP - DETERMINE: A pioneering UK precision medicine trial for rare cancers
Presenter: Gary Middleton
Session: Poster session 17
717TiP - An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
Presenter: Marta Dudek
Session: Poster session 17
718TiP - DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy
Presenter: Elizabeth Moser
Session: Poster session 17
719TiP - A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
Presenter: Michele Moschetta
Session: Poster session 17